Xeris Biopharma Holdings, Inc. XERS Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s operating lease right-of-use asset amortization?
- Xeris Biopharma Holdings, Inc. (XERS) reported operating lease right-of-use asset amortization of $163K in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s operating lease right-of-use asset amortization increased by 38.1% year-over-year, from $118K to $163K.